Latest It Distribution News

BWP Property Group and BWP Trust have launched a new Distribution Reinvestment Plan allowing stapled securityholders to reinvest cash distributions into additional securities, potentially at a discount and without transaction costs.

N1 Holdings reports a profitable FY2025 with strategic expansion into Australia's largest aggregator panel and launches AI-driven credit tools to enhance SME lending operations.

GTN Limited shareholders have overwhelmingly approved a capital return, setting the stage for a payment scheduled on 11 August 2025. This move reflects the company’s ongoing strategy to optimise shareholder value.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Bannerman Energy reports robust progress on its Etango Uranium Project, achieving key construction milestones and securing A$85 million in fresh equity to fuel its path to a Final Investment Decision.

Strickland Metals reports robust drilling results at its Serbian Rogozna Project, confirming significant gold and base metal mineralisation, while securing a $45 million equity deal for its Yandal Project in Western Australia.

TALi Digital has acquired the You Can Do It! education program, boosting its social-emotional learning portfolio, while raising $0.8 million through a private placement to support growth initiatives.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

De.mem Limited has reported its second highest quarterly cash receipts ever, alongside a fourth consecutive quarter of positive operating cash flow, positioning the company for a record full-year 2025 performance.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.